Anika Therapeutics (ANIK) Shares Outstanding (Weighted Average) (2010 - 2026)

Anika Therapeutics (ANIK) has 17 years of Shares Outstanding (Weighted Average) data on file, last reported at $13.5 million in Q1 2026.

• Shares Outstanding (Weighted Average) for Q1 2026 came in at $13.5 million, down 5.36% year-over-year; the trailing twelve-month figure through Mar 2026 was $13.5 million (down 5.36% YoY), and the FY2025 annual result was $14.3 million, down 2.59% from the prior year.
• Shares Outstanding (Weighted Average) eased to $13.5 million in Q1 2026 per ANIK's latest filing, from $14.3 million in the prior quarter.
• Over five years, Shares Outstanding (Weighted Average) peaked at $14.8 million in Q2 2024 and troughed at $13.5 million in Q1 2026.
• A 5-year average of $14.5 million and a median of $14.6 million in 2022 frame the typical range for Shares Outstanding (Weighted Average).
• The sharpest annual moves came in 2023 and 2026: Shares Outstanding (Weighted Average) climbed 1.29% in 2023, then fell 5.36% in 2026.
• A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $14.6 million in 2022, then grew by 0.65% to $14.7 million in 2023, then gained by 0.44% to $14.7 million in 2024, then fell by 2.59% to $14.3 million in 2025, then slipped by 5.63% to $13.5 million in 2026.
• Business Quant data shows ANIK's Shares Outstanding (Weighted Average) at $13.5 million in Q1 2026, $14.3 million in Q4 2025, and $14.4 million in Q3 2025.